Colorectal Cancer: Immediate Impact of 2014 ASCO Presentations on Clinical Practice

Introduction

In an effort to provide you with timely market feedback from ASCO 2014, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ from the meeting. This first report explored presentations in colorectal cancers (CRC).

OncoPoll™ Methodology

  • Primary research phase involved a global survey to verified and validated medical oncologists and multi-disciplinary physicians with an identified clinical interest in gastrointestinal cancers utilizing targeting parameters within the proprietary MDoutlook® global cancer treater database
  • Timing: June 2014. Launched two days after close of 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL., May 30-June 3, 2014
  • Fielding via <10 minute long interactive internet survey utilizing proven effective methodology via the MDoutlook survey tool
  • Links to discussed abstracts on the ASCO website were provided within the survey
  • Reponses at data collection: 50 on June 24th
  • No financial incentives provided for participation

Geographic Distribution of Respondents

Attendance at 2014 ASCO Annual Meeting

Key Conclusions

  • Nearly three quarters of survey respondents attended this year’s ASCO annual meeting
  • Higher proportion of attendees than in previous years (typically has been a 50/50 split)

Survey Participants’ GI Cancer Patient Flow:  Average Over 13 Cases Each Month

Key Conclusions

  • Survey participants* averaged 35 cases of colorectal cancer last 3 months
    • More than all other gastrointestinal cancers combined
  • Cases of pancreatic cancer were much more common than HCC

* Survey Participants = Medical Oncologists with an identified clinical interest in gastrointestinal cancers

Inclusion of Bevacizumab or Cetuximab with 1st Line Chemotherapy for KRASWT mCRC: Impact of the CALGB/SWOG 80405 Trial

Key Conclusions

  • Results of the CALGB/SWOG 80405 Trial are not going to change treatment usage in the 1st line setting
    • Small increases in cetuximab usage are expected, but not at the expense of bevacizumab
  • Inclusion of biologics with chemotherapy for 1st line setting is going to remain the standard of care
    • FOLFOX is and will remain the standard chemotherapy backbone for mCRC

Adjuvant Chemotherapy for Localized Rectal Cancer: Impact of the ADORE Trial Results

Key Conclusions

  • Oncologists recognize the clinical importance of the ADORE trial
    • Over half rate the presentation as important or higher
  • Due to these results, usage of adjuvant therapy for stage II rectal cancer is expected to increase by over 1/3 from current levels
    • Usage will be nearly 60% of the amount for stage III disease
  • Widespread usage of adjuvant therapy for stage III disease will continue
    • Slight increase to 80% of cases

Conclusions: Impact of ASCO 2014 on Clinical Practices for Colorectal Cancers

  • Colorectal cancer is the main type of gastrointestinal cancers seen in clinical practices
    • Oncologists’ patient flow in colorectal cancer is ~85% of their GI cancer patient flow
  • FOLFOX + bevacizumab is and will remain the most common 1st line treatment approach for KRASWT metastatic colorectal cancer
    • Minor increases in usage of cetuximab are expected, but not at the expense of bevacizumab
    • Chemotherapy with a biologic is the standard of care in the 1st line setting
    • FOLFOX will continue to be preferred over FOLFIRI
  • Adjuvant chemotherapy is seen as an important therapeutic approach for stage II and III rectal cancers
    • A 35% increase in its usage for stage II disease is expected, so that nearly half of patients will receive it
    • Widespread usage for stage III disease will expand even more, to 80% of patients
  • Oncologists use a wide variety of sources to learn about the results presented at ASCO

For a more detailed analysis report, please click here to download the full report.

Submitted by Robert Stephan, Sr. Director Medical Services and Strategy; Jessica Harnisch, Assoc. Global Medical Analyst; Justin Boag, Consultant; and Jan Heybroek, President MDoutlook.

– See more at: http://www.obroncology.com/blog/2014/06/1944/#sthash%2Ew1m9fkiN%2Edpuf